TECHNOLOGY BRIEFINGS Sample Clauses

TECHNOLOGY BRIEFINGS. In order that employees can better prepare themselves for the skill requirements of the future, and in fulfillment of its obligation to provide information to the Union Grievance/Negotiating Committee, the Company will, not less than quarterly, provide a briefing to the Union Grievance/Negotiating Committee of the Company's plans for the introduction of new technology which may affect the employees. During these briefings, the Company will inform the Union Grievance/Negotiating Committee of anticipated schedules of introduction of new technology, and will identify areas of skill impacts and any intended training programs associated with those impacts. Included will be briefings on the implementation of computer- based systems that will result in the displacement of employees. The Union and its representatives will protect the confidentiality of Company sensitive and proprietary information disclosed in the briefings.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
TECHNOLOGY BRIEFINGS. On at least a quarterly basis (under NDA), OneSoft will brief USWeb/CKS on future OneSoft product directions and USWeb/CKS will brief OneSoft on future iFrame and iAMsystem directions. OneSoft Beta Products. OneSoft will exercise commercially reasonable effort to provide beta release software to USWeb/CKS before general release and in any event no later than general release to OCPs.
Sample 1Sample 2
TECHNOLOGY BRIEFINGS. 29 In order that employees can better prepare themselves for the skill 30 requirements of the future, and in fulfillment of its obligation to provide 31 information to the Union, the Company will not less than each six (6) 32 months provide a briefing to the Union of the Company’s plans for the 33 introduction of technological change which may affect employees. These 34 briefings may be combined with briefings to the Hazard Communication 35 Team under Section 16.2(e). The Union and its representatives will protect 36 the confidentiality of Company sensitive and proprietary information 37 disclosed in the briefings. 38 During these briefings, the Company will inform the Union of anticipated 39 schedules of introduction of new technology, and will identify areas of skill 40 impacts. In addition, when the Company intends to implement a 41 technological improvement in its tools, methods, processes, equipment or 42 materials which could have an impact on the work performed by bargaining 43 unit employees, the Company will advise the Union of the nature and 1 location of such technological changes and the extent to which they may 2 affect the work performed by those employees. 3 The Company and the Union agree that this Section 21.9 fully sets forth the 4 Company’s obligation to provide information concerning new technology 5 or any other introduction or technological improvement of new machines, 6 tools, methods, processes, equipment and/or materials. If the Union 7 requests other information related to these matters, the request will be 8 treated as a request to add additional subjects to the briefings.
Sample 1
TECHNOLOGY BRIEFINGS. In order that employees can better prepare themselves for the skill requirements of the future, and in fulfillment of its obligation to provide information to the Union, the Company will, not less than semi-annually provide a briefing to the Union of the company's plans for the introduction of new technology which may affect the employees. During these briefings, the company will inform the Union of anticipated schedules of introduction of new technology, and will identify areas of skill impacts and any intended training programs associated with those impacts. Included will be briefings on the implementation of computer-based systems that will result in the displacement of employees. The Union, and its representatives, will protect the confidentiality of company sensitive and proprietary information disclosed in the briefings.
Sample 1
TECHNOLOGY BRIEFINGS. In order that Employees can better prepare themselves for the skill requirements of the future, the Company will provide a semi-annual briefing to the Union leadership of the Company’s plans for the introduction of new technology which may affect the Employees. During these briefings, the Company will inform the Union leadership of anticipated schedules of introduction of new technology and will identify areas of skill impacts and any intended training programs associated with those impacts. The Union and its representatives will protect the confidentiality of Company sensitive and proprietary information disclosed in the briefings.
Sample 1

Related to TECHNOLOGY BRIEFINGS

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Training a. The employer, in consultation with the local, shall be responsible for developing and implementing an ongoing harassment and sexual harassment awareness program for all employees. Where a program currently exists and meets the criteria listed in this agreement, such a program shall be deemed to satisfy the provisions of this article. This awareness program shall initially be for all employees and shall be scheduled at least once annually for all new employees to attend.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.